

BRONCAST[®] Montelukast 4mg & 5mg

The reliable choice in
long term management
of asthma in children



 **Avalon** Pharma




BRONCAST

Montelukast 4mg & 5mg

ADD-ON THERAPY
FOR BETTER ASTHMA
CONTROL


High efficacy in improving activity & alleviating symptoms in children suffering from asthma¹

Efficacy of Montelukast (Broncast) versus placebo in reducing the number of children's visits to the GP and emergency department attendance.



High tolerability for children²

Change in Height (cm) from Randomization Visit by Scheduled Week²



A 56-week, multi-center, double-blind, randomized, active and placebo-controlled parallel group study was conducted to assess the effect of MONTELUKAST* on growth rate in 360 patients with mild asthma, aged 6 to 8 years. Treatment groups included MONTELUKAST* 5 mg once daily, placebo, and beclomethasone.

Treatment with Montelukast* 5mg daily for 56 weeks did not suppress growth rate in pediatric patients aged 6 to 8 years.

Dosage & Administration

Paediatric patients 2 to 5 years of age : one 4-mg chewable tablet daily to be taken at bed time. No dosage adjustment within this age group is necessary

Pediatric patients 6 to 14 years of age: one 5-mg chewable tablet daily to be taken at bed time. No dosage adjustment within this age group is necessary

* Montelukast is the active ingredient of Broncast.

1. American journal of respiratory and critical care medicine vol 2007 175

2. Annals of Allergy, Asthma & Immunology Volume 96, issue 6, June 2006, Pages 800-807.